Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine)

P4, N=1266, Not yet recruiting, International Agency for Research on Cancer

We report the case of a 37-year-old female with psoriasis who, after achieving stable disease control on ixekizumab, developed widespread eruptive brown macules, patches, and papules within one month of receiving a quadrivalent HPV vaccine...The lesions faded following oral acitretin therapy...We discuss potential mechanisms, propose clinical management considerations, and provide insights that may inform future research and clinical practice. The ultimate aim is to contribute to the refinement of guidelines on vaccination in patients receiving biologic therapy for psoriasis, ensuring both therapeutic efficacy and patient safety.

P3, N=52, Completed, University of Pretoria | Active, not recruiting --> Completed | N=75 --> 52 | Trial completion date: Jul 2027 --> Jul 2025 | Trial primary completion date: Jul 2026 --> Jul 2025

In women aged 20 to 24 with 40% uptake of quadrivalent HPV vaccine, overall HPV prevalence dropped from 25.3% to 12.8% (p < 0.001)... The first large-scale, systematic, and methodologically consistent study of HPV vaccine effectiveness in CEE showed a substantial reduction in high-risk HPV prevalence after implementation of the national program, with the greatest decline among women aged 20 to 24, who harbored the highest HPV burden in the pre-vaccination era. These locally acquired data will considerably inform public health strategies on cervical cancer elimination in CEE.

Adjuvants in the bivalent HPV vaccine (2vHPV) and quadrivalent HPV vaccine (4vHPV) are AS04 [composed of aluminum (Al) hydroxide (AH) and monophosphoryl lipid A (MPL)] and Al hydroxyphosphate sulfate (AHS), respectively...Experiments using IL-18 receptor-deficient mice and AS01 injection alone demonstrated that IL-18 and AS01 contributed to weight loss. Since 2vHPV containing AS04 (AH and MPL) did not induce weight loss, QS-21, but not MPL, in AS01 seemed responsible for weight loss, demonstrating the safety of MPL.

Among HR-HPV-positive samples, 87.5% (21/24) were genotypes targeted by the Gardasil vaccine, while 12.5% (3/24) were non-vaccine types...In the hinterland of Gabon, WLWH are facing an unsuspected yet substantial burden of cervical HR-HPV infection and a neglected risk for cervical cancer. Strengthening cervical cancer prevention through targeted HPV vaccination, sexual education, and accessible screening strategies will help in mitigating associated risk.

P3, N=12167, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P3, N=75, Active, not recruiting, University of Pretoria | Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: May 2025 --> Jul 2026

P2, N=76, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed

P2, N=120, Recruiting, University of Maryland, Baltimore | Not yet recruiting --> Recruiting

P2, N=120, Not yet recruiting, University of Maryland, Baltimore | N=180 --> 120

P3, N=0, Withdrawn, Merck Sharp & Dohme LLC | N=600 --> 0 | Suspended --> Withdrawn